Research
Hormonal
SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.
SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.
GoodQualifiesMEDIUM confidence
While these experiments provide some support for interaction between SGLT receptor blockade and sympathetic nervous activity, short-term treatment with empagliflozin in patients with type 2 diabetes had no effect on MSNA.
Why this rating
Based on meta-analyses and specific human trials cited.
Source
The Influence of the Sympathetic Nervous System on Cardiometabolic Health in Response to Weight Gain or Weight Loss
Gavin Lambert et al. · Metabolites · 2025
DOI 10.3390/metabo15050286
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and weight gain drive regional sympathetic nervous system activation, which initiates and worsens cardiometabolic risk factors including hypertension, insulin resistance, and dyslipidemia.Good
- GLP-1 receptor agonists reduce cardiovascular risk and promote weight loss, but they cause a transient increase in heart rate that is independent of sympathetic nervous system activation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →